AU2001268322A1 - Antisense modulation of c/ebp alpha expression - Google Patents
Antisense modulation of c/ebp alpha expressionInfo
- Publication number
- AU2001268322A1 AU2001268322A1 AU2001268322A AU6832201A AU2001268322A1 AU 2001268322 A1 AU2001268322 A1 AU 2001268322A1 AU 2001268322 A AU2001268322 A AU 2001268322A AU 6832201 A AU6832201 A AU 6832201A AU 2001268322 A1 AU2001268322 A1 AU 2001268322A1
- Authority
- AU
- Australia
- Prior art keywords
- alpha expression
- antisense modulation
- ebp alpha
- ebp
- antisense
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- 230000000692 anti-sense effect Effects 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/31—Chemical structure of the backbone
- C12N2310/315—Phosphorothioates
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/32—Chemical structure of the sugar
- C12N2310/321—2'-O-R Modification
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/33—Chemical structure of the base
- C12N2310/334—Modified C
- C12N2310/3341—5-Methylcytosine
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/34—Spatial arrangement of the modifications
- C12N2310/341—Gapmers, i.e. of the type ===---===
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/34—Spatial arrangement of the modifications
- C12N2310/346—Spatial arrangement of the modifications having a combination of backbone and sugar modifications
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
- Y02P20/00—Technologies relating to chemical industry
- Y02P20/50—Improvements relating to the production of bulk chemicals
- Y02P20/582—Recycling of unreacted starting or intermediate materials
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Genetics & Genomics (AREA)
- Public Health (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Biomedical Technology (AREA)
- Biotechnology (AREA)
- Molecular Biology (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- General Engineering & Computer Science (AREA)
- Diabetes (AREA)
- Microbiology (AREA)
- Plant Pathology (AREA)
- Biochemistry (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Physics & Mathematics (AREA)
- Biophysics (AREA)
- Rheumatology (AREA)
- Pain & Pain Management (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Child & Adolescent Psychology (AREA)
- Emergency Medicine (AREA)
- Endocrinology (AREA)
- Gastroenterology & Hepatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US09/593,589 US6306655B1 (en) | 2000-06-13 | 2000-06-13 | Antisense inhibition of C/EBP alpha expression |
US09593589 | 2000-06-13 | ||
PCT/US2001/018803 WO2001096586A1 (en) | 2000-06-13 | 2001-06-11 | Antisense modulation of c/ebp alpha expression |
Publications (1)
Publication Number | Publication Date |
---|---|
AU2001268322A1 true AU2001268322A1 (en) | 2001-12-24 |
Family
ID=24375326
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
AU2001268322A Abandoned AU2001268322A1 (en) | 2000-06-13 | 2001-06-11 | Antisense modulation of c/ebp alpha expression |
Country Status (5)
Country | Link |
---|---|
US (1) | US6306655B1 (en) |
EP (1) | EP1290204A1 (en) |
JP (1) | JP2004503246A (en) |
AU (1) | AU2001268322A1 (en) |
WO (1) | WO2001096586A1 (en) |
Families Citing this family (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7407943B2 (en) * | 2001-08-01 | 2008-08-05 | Isis Pharmaceuticals, Inc. | Antisense modulation of apolipoprotein B expression |
ES2420914T3 (en) * | 2002-11-13 | 2013-08-27 | Genzyme Corporation | Antisense modulation of apolipoprotein B expression |
CA2682082A1 (en) | 2007-03-24 | 2008-10-02 | Genzyme Corporation | Administering antisense oligonucleotides complementary to human apolipoprotein b |
US10941399B2 (en) * | 2011-04-14 | 2021-03-09 | Beth Israel Deaconess Medical Center, Inc. | Methods and compositions for gene-specific demethylation by DNA methyltransferase (DNMT)-RNA interaction |
EP4060043A1 (en) | 2011-06-21 | 2022-09-21 | MiNA Therapeutics Limited | Albumin production and cell proliferation |
DK3071696T3 (en) * | 2013-11-22 | 2019-10-07 | Mina Therapeutics Ltd | C / EBP ALFA SHORT ACTIVATION RNA COMPOSITIONS AND METHODS OF USE |
Family Cites Families (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH08509863A (en) | 1993-03-04 | 1996-10-22 | ベイラー・カレッジ・オブ・メディシン | Human C / EBP gene and vector for its expression |
US5801154A (en) * | 1993-10-18 | 1998-09-01 | Isis Pharmaceuticals, Inc. | Antisense oligonucleotide modulation of multidrug resistance-associated protein |
-
2000
- 2000-06-13 US US09/593,589 patent/US6306655B1/en not_active Expired - Lifetime
-
2001
- 2001-06-11 JP JP2002510700A patent/JP2004503246A/en not_active Withdrawn
- 2001-06-11 EP EP01946246A patent/EP1290204A1/en not_active Withdrawn
- 2001-06-11 WO PCT/US2001/018803 patent/WO2001096586A1/en not_active Application Discontinuation
- 2001-06-11 AU AU2001268322A patent/AU2001268322A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
EP1290204A1 (en) | 2003-03-12 |
WO2001096586A1 (en) | 2001-12-20 |
JP2004503246A (en) | 2004-02-05 |
US6306655B1 (en) | 2001-10-23 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AU2001289085A1 (en) | Antisense modulation of flip-c expression | |
AU2212600A (en) | Antisense modulation of g-alpha-i1 expression | |
AU6296099A (en) | Antisense modulation of g-alpha-12 expression | |
AU2001229493A1 (en) | Antisense modulation of mekk2 expression | |
AU2002309819A1 (en) | Antisense modulation of PTP1B expression | |
AU2002227435A1 (en) | Antisense modulation of calreticulin expression | |
AU6296199A (en) | Antisense modulation of smad1 expression | |
AU2001229447A1 (en) | Antisense modulation of smad7 expression | |
AU2001278077A1 (en) | Antisense modulation of ptp1b expression | |
AU2001261808A1 (en) | Antisense modulation of pten expression | |
AU2001263171A1 (en) | Antisense modulation of tert expression | |
AU2001239971A1 (en) | Antisense modulation of parp expression | |
AU6115400A (en) | Antisense modulation of mekk5 expression | |
AU2001227847A1 (en) | Antisense modulation of pepck-cytosolic expression | |
AU7876900A (en) | Antisense modulation of fra-1 expression | |
AU2002366788A1 (en) | Antisense modulation of ship-1 expression | |
AU2001288968A1 (en) | Antisense modulation of btak expression | |
AU2001268307A1 (en) | Antisense modulation of c/ebp beta expression | |
AU2001257220A1 (en) | Antisense modulation of inhibitor of dna binding-1 expression | |
AU2002318139A1 (en) | Antisense modulation of src-c expression | |
AU2209000A (en) | Antisense modulation of pepck-mitochondrial expression | |
AU2002230869A1 (en) | Antisense modulation of hepsin expression | |
AU5486700A (en) | Antisense modulation of g-alpha-s1 expression | |
AU2002226064A1 (en) | Antisense modulation of talin expression | |
AU2002357102A1 (en) | Antisense modulation of cd36l1 expression |